tiprankstipranks
Trending News
More News >

Fosun Pharma’s Subsidiary Gains Approval for New Breast Cancer Drug

Story Highlights
  • Fosun Pharma’s subsidiary received approval for Fovinaciclib Citrate Capsules.
  • The drug targets HR-positive, HER2-negative breast cancer, boosting Fosun’s oncology portfolio.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Fosun Pharma’s Subsidiary Gains Approval for New Breast Cancer Drug

Confident Investing Starts Here:

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.

Shanghai Fosun Pharmaceutical announced that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration of Fovinaciclib Citrate Capsules. This new drug is intended for use in combination with Fulvestrant to treat adult patients with hormone receptor-positive and HER2-negative recurrent or metastatic breast cancer, marking a significant step in the company’s oncology portfolio and potentially enhancing its market position in cancer treatment solutions.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and manufacturing of pharmaceuticals, with a market emphasis on innovative drug solutions.

Average Trading Volume: 4,628,611

Technical Sentiment Signal: Hold

Current Market Cap: HK$62.5B

See more insights into 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App